Figure 1.
Flow chart of infectious risk assessment
* to evaluate new infections acquired during DMT or the reactivation of latent infection. The evaluation was performed after six months for injective DMTs and after twelve months for oral DMTs.
** serial assessment based on the infectious risk and first-level of infectious risk assessment after six months.